- Home
- MTA vs HRTX Comparison
MTA vs HRTX Comparison
Compare MTA & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- HRTX
- Stock Information
- Founded
- MTA 1983
- HRTX 1983
- Country
- MTA Canada
- HRTX United States
- Employees
- MTA N/A
- HRTX N/A
- Industry
- MTA
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- MTA
- HRTX Health Care
- Exchange
- MTA Nasdaq
- HRTX Nasdaq
- Market Cap
- MTA 264.7M
- HRTX 240.3M
- IPO Year
- MTA N/A
- HRTX 1987
- Fundamental
- Price
- MTA $2.60
- HRTX $1.59
- Analyst Decision
- MTA
- HRTX Strong Buy
- Analyst Count
- MTA 0
- HRTX 3
- Target Price
- MTA N/A
- HRTX $5.67
- AVG Volume (30 Days)
- MTA 452.6K
- HRTX 6.2M
- Earning Date
- MTA 11-14-2024
- HRTX 11-12-2024
- Dividend Yield
- MTA N/A
- HRTX N/A
- EPS Growth
- MTA N/A
- HRTX N/A
- EPS
- MTA N/A
- HRTX N/A
- Revenue
- MTA $5,048,000.00
- HRTX $137,737,000.00
- Revenue This Year
- MTA $44.57
- HRTX $13.10
- Revenue Next Year
- MTA $126.18
- HRTX $18.76
- P/E Ratio
- MTA N/A
- HRTX N/A
- Revenue Growth
- MTA 28.55
- HRTX 12.13
- 52 Week Low
- MTA $2.32
- HRTX $1.04
- 52 Week High
- MTA $4.08
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- MTA 30.99
- HRTX 50.28
- Support Level
- MTA $2.62
- HRTX $1.53
- Resistance Level
- MTA $2.85
- HRTX $1.88
- Average True Range (ATR)
- MTA 0.13
- HRTX 0.17
- MACD
- MTA -0.01
- HRTX 0.01
- Stochastic Oscillator
- MTA 3.74
- HRTX 47.67
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.